DHA, Toronto’s Mount Sinai Hospital and AstraZeneca Gulf sign MoU

United Arab Emirates: Tuesday, January 24 - 2012 @ 13:36

The pulmonary medicine update course will provide respiratory care educators, researchers, practitioners and providers of health care with the tools they need to improve respiratory patient outcomes.

Present at the signing ceremony, His Excellency Qadhi Murooshid, Director General of Dubai Health Authority, said: “We put significant emphasis on training, which is why we are very glad to partner with the Peter A. Silverman Centre and AstraZeneca Gulf. Medicine is ever evolving, and therefore continuous medical education is vital to ensure that physicians are kept up to date within their field.”

Dr. Khalil Qayed, Director of Medical Education at the DHA, said: “The DHA fosters the continuous progress and development of our employees through sustained medical educations programmes like this one. This course is of significance to all primary healthcare physicians as it provides the latest tools and information for asthma management and care.”

Asthma, one of many lung diseases, affects 235 million people worldwide and is one of the most common chronic diseases among children. Every year, 250,000 people die of asthma worldwide, which means that someone dies every two minutes. Asthma also represents a considerable burden on healthcare systems worldwide. Asthma is a chronic disease characterized by recurrent attacks of breathlessness and wheezing, which vary in severity and frequency from person to person. While asthma cannot be cured, with proper treatment and management symptoms can be controlled, and patients can reach a good quality of life.

Representing the University of Toronto and the Peter A. Silverman Centre, Dr. Thomas Stewart, Physician-in-Chief and Chief Clinical Officer, Mount Sinai Hospital, Sandra and Lionel Waldman Family Chair and Professor of Medicine and Anaesthesia, said: “This programme will give participants access to the latest advancements in diagnosis and management of pulmonary disorders, as well as guidance from renowned experts that can be applied to their own practices. The aim here is to raise the quality of care that the patients receive so that they can enjoy a better quality of life.”

Sponsored by AstraZeneca Gulf and implemented by DHA, the pulmonary medicine update course will expose participants to the thinking and practice of internationally recognised experts, as well as a broad array of tools, guidelines and frameworks to help them keep up with the latest information, procedures, techniques and data.

At the completion of the programme, participants will be equipped with the tools to apply lessons from others in the field, implement measurable goals, and establish long-term strategic planning for overall performance improvement. The proposed programme will include a personal learning plan, virtual mentoring and online lectures, and participants will benefit from an extensive library of online resources. The first batch of specialists will be from DHA, who will then be qualified to teach other specialists in the Gulf.

Samer Al Hallaq, AstraZeneca Gulf President, said: “Working alongside the Dubai Health Authority, Peter A. Silverman Centre and the University of Toronto, this course is a clear example of how we can put patient needs at the centre of our endeavours and search for the best available tools to help healthcare professionals. At AstraZeneca, we understand the importance of how Health Connects Us All, and we continue to look for ways beyond medicines to help in the fight against respiratory and pulmonary disorders around the world, and specifically here in the UAE.”

Today's Top Stories

Posted by

Tuesday, January 24- 2012 @ 13:36 UAE local time (GMT+4) Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of Mediaquest FZ LLC.

AME Info Services

Business DirectoryVIEW ALL

Search by name

Search by industry

Browse alphabetically


Search for jobs

Latest Jobs